Acquired Immunodeficiency Syndrome Clinical Trial
Official title:
Couples HIV Intervention Randomized Controlled Trial
Recent studies have shown that many drug-using minority women are vulnerable to HIV infection from their husbands or other intimate male partners. The goal of this study is to develop and evaluate two new HIV counseling and testing programs designed for drug-using women at risk for HIV from a primary male partner. It is predicted that HIV counseling and testing programs administered to couples rather than to women only, and programs that focus on intimate relationships in the context of HIV risk, will result in a reduction of risky sexual and drug-related behavior among drug-using women and their primary male partners. This four-year study employs a randomized clinical trial (RCT) design to test the effectiveness of two new HIV counseling and testing programs for women drug-users in Harlem and the South Bronx in New York City.
The broad, long-term objective of this research is to establish primary preventive
interventions to reduce human immunodeficiency virus (HIV) risk behavior among drug-using
minority women. Recent studies indicate that high rates of sexual risk behavior occur within
drug-using minority women's primary heterosexual relationships. Based on an integrated
theory of HIV risk behavior, it is predicted that (a) interventions administered to couples
rather than to women only, and (b) interventions that focus on relationship dynamics in the
context of HIV risk, will result in a reduction of sexual and drug-related risk behavior
among drug-using women and their primary partners. This four-year study employs a randomized
clinical trial (RCT) 3-group design to test the efficacy of HIV intervention modality
(couples versus women-only) and intervention content (relationship-focused versus standard
HIV counseling and testing) on crack, cocaine and heroin (injected and noninjected) using
women's sexual risk with primary partners.
A total of 390 women drug-users and their partners are recruited from the streets of Harlem
and the South Bronx in New York City. Participants are randomly assigned to one of three HIV
counseling and testing intervention conditions: (a) couples, relationship-focused; (b)
women-only, relationship-focused; or, (c) NIDA women-only standard HIV-CT (control). All
subjects are administered baseline, 3-month, and 9-month follow-up assessments using a
combination of computer-assisted personal interview (CAPI) and computer-assisted self
interview (CASI) techniques. In addition to sociodemographic characteristics, the interview
will measure drug-use patterns, HIV risk behavior, and dyadic- and individual-level
variables operationalized to test specific hypotheses of women's HIV risk behavior and
behavior change. In addition to testing the effectiveness of the experimental interventions,
data analyses will determine the theory-driven psychosocial mechanisms that act to mediate
and moderate any observed association between intervention treatment and subsequent risk
reduction. Incremental cost-effectiveness analyses will also be performed.
Results from this study will allow researchers to determine whether couple-based HIV
counseling and testing is a more effective (and cost-effective) approach to HIV prevention
than individual HIV counseling and testing. Analyses will further provide information on the
specific components of couple-based interventions that were most effective in reducing HIV
risk behavior, thereby contributing to theory development regarding intimate couples' HIV
risk.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01968551 -
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
|
Phase 3 | |
Completed |
NCT02929069 -
A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk
|
N/A | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT02264509 -
Peripheral Arterial Insufficiency Associated With HIV/AIDS
|
N/A | |
Completed |
NCT02583464 -
Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.
|
Phase 1 | |
Completed |
NCT01440569 -
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
|
Phase 3 | |
Completed |
NCT00551330 -
Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)
|
Phase 2 | |
Completed |
NCT00381212 -
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
|
Phase 1/Phase 2 | |
Completed |
NCT00097006 -
Retrovirus Epidemiology Donor Study-II (REDS-II)
|
N/A | |
Completed |
NCT00001409 -
Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications
|
Phase 1 | |
Completed |
NCT00000590 -
Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)
|
Phase 3 | |
Completed |
NCT00000587 -
Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection
|
Phase 2 | |
Completed |
NCT00005273 -
Pulmonary Complications of HIV Infection Study (PACS)
|
N/A | |
Completed |
NCT00005303 -
Effectiveness of AIDS Antibody Screening
|
N/A | |
Completed |
NCT00005301 -
Transfusion Safety Study (TSS)
|
N/A | |
Completed |
NCT00001650 -
Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients
|
N/A | |
Withdrawn |
NCT00243568 -
Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285
|
Phase 3 | |
Recruiting |
NCT05031819 -
Managing Hypertension Among People Living With HIV
|
N/A | |
Completed |
NCT00394004 -
Decision-Making of Hispanics and African-Americans With HIV/AIDS Participating in Clinical Trials
|
N/A | |
Completed |
NCT01967940 -
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
|
Phase 3 |